Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of ECF/TAF Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection
NCT02660905Phase 3Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Apr 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir alafenamide, ledipasvir in human immunodeficiency virus infection (HIV), hepatitis C (HCV), sponsored by Ottawa Hospital Research Institute. Started Apr 2016; status: completed.
02
Drugs
tenofovir alafenamideledipasvir
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02660905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660905.